The use of Janus kinase inhibitors in the time of SARS-CoV-2.

J Am Acad Dermatol. 2020 Apr 9. pii: S0190-9622(20)30522-3

Effect of High vs Low Doses of Chloroquine Diphosphateas Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.

JAMA Netw Open. 2020;3(4.23):e208857.


SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options.

Eur Rev Med Pharmacol Sci 2020; 24 (7): 4016-4026

DOI: 10.26355/eurrev_202004_20871

COVID-19: lambda interferon against viral load and hyperinflammation.

EMBO Mol Med. 2020 Apr 25.

Extracorporeal Life Support Organization COVID-19 Interim Guidelines

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.

J Crit Care. 2020 Mar 10. pii: S0883-9441(20)30390-7

Coronaviruses — drug discovery and therapeutic options.

Nat Rev Drug Discov. 2016 May;15(5):327-47.


COVID-19: combining antiviral and anti-inflammatory treatments.

Lancet Infect Dis. 2020 Apr;20(4):400-402

Current Drugs with Potential for Treatment of COVID-19: A Literature Review.

J Pharm Pharm Sci. 2020;23(1):58-64

Covid-19 — The Search for Effective Therapy.

N Engl J Med. 2020 Mar 18.

DOI: 10.1056/NEJMe2005477

Current status of potential therapeutic candidates for the COVID-19 crisis.

Brain Behav Immun. 2020 Apr 22

Manejo clínico de la infección respiratoria aguda grave presuntamente causada por el nuevo coronavirus (2019-nCoV).

Manejo clínico de la infección respiratoria aguda grave (IRAG) en caso de sospecha de COVID-19

Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19.

J Clin Med. 2020 Apr 15;9(4)


Treatment options for COVID-19: The reality and challenges.

J Microbiol Immunol Infect. 2020 Apr 4. pii: S1684-1182(20)30094-3

COVID-2019: update on epidemiology, disease spread and management.

Monaldi Arch Chest Dis. 2020 Apr 16;90(1)

Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options

Open Forum Infect Dis. 2020 Mar 23;7(4):ofaa105

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.

J Biol Chem. 2020 Apr 13. pii: jbc.RA120.013679.

Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.

Antiviral Res. 2020 Apr 10;178:104793.

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.

JAMA. 2020 Apr 13

Compassionate Use of Remdesivir for Patients with Severe Covid-19.

N Engl J Med. 2020 Apr 10

DOI: 10.1056/NEJMoa2007016

Lineamiento para la atención de pacientes por COVID-19.

Comentarios desactivados en TRATAMIENTO COVID 19